Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 20:11:787-796.
doi: 10.1016/j.dadm.2019.07.003. eCollection 2019 Dec.

The Consortium for the early identification of Alzheimer's disease-Quebec (CIMA-Q)

Sylvie Belleville  1   2 , Andréa C LeBlanc  3   4 , Marie-Jeanne Kergoat  2   5 , Frédéric Calon  6   7 , Pierrette Gaudreau  8   9 , Sébastien S Hébert  7   10 , Carol Hudon  11   12 , Nicole Leclerc  9   13 , Naguib Mechawar  14   15 , Simon Duchesne  12   16 , Serge Gauthier  14   17 ; Consortium for the Early Identification of Alzheimer's disease-Quebec (CIMA-Q)
Collaborators, Affiliations

The Consortium for the early identification of Alzheimer's disease-Quebec (CIMA-Q)

Sylvie Belleville et al. Alzheimers Dement (Amst). .

Abstract

Introduction: The Consortium for the early identification of Alzheimer's disease-Quebec (CIMA-Q) created a research infrastructure to recruit, characterize, and track disease progression in individuals at risk of dementia.

Methods: CIMA-Q established standardized clinical, neuropsychological, neuroimaging, blood (plasma, serum, RNA, genomic DNA), cryopreserved peripheral blood mononuclear cells, and cerebrospinal fluid collection protocols. These data and biological materials are available to the research community.

Results: In phase 1, 115 persons with subjective cognitive decline, 88 with mild cognitive impairment, 31 with early probable Alzheimer's disease, and 56 older adults with no worries nor impairments received detailed clinical and cognitive evaluations as well as blood and peripheral blood mononuclear cells collections. Among them, 142 underwent magnetic resonance imaging, 29 a 18fluorodeoxyglucose positron emission tomography, and 60 a lumbar puncture.

Discussion: CIMA-Q provides procedures and resources to identify early biomarkers and novel therapeutic targets, and holds promise for detecting cognitive decline in Alzheimer's disease.

Keywords: Alzheimer's disease; Biomarker; CIMA-Q; Clinical cohort; Consortium for the early identification of Alzheimer's disease-Quebec; Cryopreserved PBMNC; Early diagnosis; Mild cognitive impairment; Subjective cognitive decline.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Amyloid beta (Aβ) concentrations in cerebrospinal fluid samples from the CIMA-Q cohort. (A) Aβ38, (B) Aβ40, and (C) Aβ42 in pg/ml of the CSF from control (CTL) individuals and individuals with subjective cognitive decline (SCD), early mild cognitively impaired (eMCI), late MCI, and Alzheimer's disease (AD). Each dot represents one individual in the category. (D–F) Ratios of Aβ42 over total Aβ (Aβ38+Aβ40+Aβ42) in each category of subjects (D), stratified into males and females (E) or per APOE genotype (F) for all subjects studied. Kruskal-Wallis statistical tests were used to analyze Aβ concentrations between diagnostic categories. The horizontal bars represent the mean. Each point represents one or several overlapping data from the individuals assessed. The Mann-Whitney statistical test was used to analyze Aβ42/total Aβ between sexes. The Kruskal-Wallis statistical test was used to analyze Aβ42 concentration between APOE genotypes. *P < 0.05, **P < 0.01. Abbreviations: CSF, cerebrospinal fluid; pg/mL, picogram/milliliter; CIMA-Q, Consortium for the early identification of Alzheimer's disease-Quιbec; APOE E, apolipoprotein E; P, probability value.
Fig. 2
Fig. 2
Total Tau concentration in cerebrospinal fluid samples from the CIMA-Q cohort. (A) Total Tau levels in pg/mL of the CSF from control (CTL) individuals and individuals with subjective cognitive decline (SCD), early mild cognitively impaired (eMCI), late MCI, and Alzheimer's disease (AD) individuals and (B) expressed relative to the age of subjects or (C) relative to males and females. Each dot represents one subject. The Kruskal-Wallis statistical tests were used to analyze total Tau levels between diagnostic categories. A Spearman correlation was used to analyze total Tau levels versus age. The horizontal bars in (A) and (C) represent the mean. Each point represents one or several overlapping data from the individuals assessed. The Mann Whitney test was used to analyze total Tau concentrations between sexes. Abbreviations: pg/mL, picogram/milliliter; CIMA-Q, Consortium for the early identification of Alzheimer's disease-Québec; R, correlation coefficient; P, probability value.
See this image and copyright information in PMC

References

    1. Bateman R.J., Xiong C., Benzinger T.L., Fagan A.M., Goate A., Fox N.C. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. New Engl J Med. 2012;367:795–804. - PMC - PubMed
    1. Albert M.S., DeKosky S.T., Dickson D., Dubois B., Feldman H.H., Fox N.C. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011;7:270–279. - PMC - PubMed
    1. Jack C.R., Jr., Albert M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011;7:257–262. - PMC - PubMed
    1. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Jr., Kawas C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's Dement. 2011;7:263–269. - PMC - PubMed
    1. Ashburner J., Csernansky J.G., Davatzikos C., Fox N.C., Frisoni G.B., Thompson P.M. Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet Neurol. 2003;2:79–88. - PubMed